Table 1.
Baseline characteristics of patients with Type II Diabetes
| Clinical Site | N (%) |
|---|---|
| Total patients | 1056 |
| Kaiser South East | 154 (15%) |
| Marshfield Clinic | 150 (14%) |
| Vanderbilt | 251 (24%) |
| Kaiser Northern California | 501 (47%) |
| Categorical Variable | N (%) |
| Males | 415 (61%) |
| Females | 641 (39%) |
| European Americans1 | 376 (36%) |
| African Americans | 665 (63%) |
| Asian Americans and Others | 15 (1%) |
| Continuous Variable | Median (range) |
| Age (years) | 55 (23–90) |
| Body weight (kg) | 96 (34–212) |
| Average Serum Creatinine (mg/dL) | 0.91 (0.5–2.0) |
| Baseline HbA1c (%) | 7.6 (5.6–17.9) (60 mmol/mol (38–172 mmol/mol) |
| Metformin daily dose (mg) | 1000 (200–2500) |
| # HbA1c samples/patient | 5 (1–45) |
| Years on study | 1.43 (0.28–13.5) |
1
Ethnicities reported are all self reported.
2
This is the average daily dose of metformin calculated from metformin start day up to the day, where minimum HbA1c levels were achieved between 3–18 months (and before other anti-diabetic drug or insulin was added). There was one patient, as noted in the electronic medical record, who had <250 mg average metformin dose due to an early stop of metformin (at 1000 mg) for several months and then restarted the metformin at 500 mg. As a result, the average metformin dose was <250mg.